PolandTuberculosis profile
Population  2016 38 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.48 (0.46–0.51) 1.3 (1.2–1.3)
Mortality (HIV+TB only) 0.027 (0.013–0.047) 0.07 (0.03–0.12)
Incidence  (includes HIV+TB) 7.1 (6–8.2) 18 (16–21)
Incidence (HIV+TB only) 0.18 (0.099–0.28) 0.47 (0.26–0.73)
Incidence (MDR/RR-TB)** 0.09 (0.066–0.11) 0.24 (0.17–0.3)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.33 (0.28–0.37) 2 (1.7–2.3) 2.3 (2–2.7)
Males 0.37 (0.31–0.42) 4.4 (3.7–5) 4.7 (4–5.5)
Total 0.69 (0.59–0.8) 6.4 (5.4–7.3) 7.1 (6–8.2)
TB case notifications, 2016  
Total cases notified 6 444
Total new and relapse 6 143
          - % tested with rapid diagnostics at time of diagnosis 14%
          - % with known HIV status  
          - % pulmonary 95%
          - % bacteriologically confirmed among pulmonary 75%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.06–0.09)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  77
(56–98)
Estimated % of TB cases with MDR/RR-TB 0.83% (0.56–1.2) 4.4% (2.7–6.8)  
% notified tested for rifampicin resistance 65% 48% 4 193
MDR/RR-TB cases tested for resistance to second-line drugs   40
Laboratory-confirmed cases MDR/RR-TB: 51, XDR-TB: 8
Patients started on treatment **** MDR/RR-TB: 46, XDR-TB: 8
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 53% 6 196
Previously treated cases, excluding relapse, registered in 2015 43% 189
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 18% 44
XDR-TB cases started on second-line treatment in 2014 20% 5
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-18 Data: www.who.int/tb/data